Offer Request Form

Order list is empty

Shikari® (Q-AF HIGH SENSITIVE) Aflibercept ELISA

Enzyme immunoassay for the quantitative determination of Aflibercept (Eylea®) in serum and plasma.

This kit has been especially developed for the quantitative determination of Aflibercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

Aflibercept Drug Bank Accession Number is DB08885.

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact

Required Volume (µl) 50
Total Time (min) 105
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 1
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions for Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action